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subjects with hepatic impairment and healthy matched con-
trols. Study progression was based on drug-related toxicity 
(CtCae v. 3.0) and Cmax of afatinib.
Results afatinib pharmacokinetic profiles and plasma 
protein binding were similar in subjects with impaired liver 
function and healthy controls. Compared with matched 
controls, the afatinib-adjusted geometric mean ratio for 
aUC0–∞ was 92.6 % (90 % CI 68.0–126.3 %) and Cmax was 
109.5 % (90 % CI 82.7–144.9 %) for subjects with mild 
hepatic impairment, and 94.9 % (90 % CI 72.3–124.5 %) 
and 126.9 % (90 % CI 86.0–187.2 %), respectively, for 
subjects with moderate hepatic impairment. For all param-
eters, the 90 % CI included 100 %. afatinib was generally 
well tolerated with no serious adverse events reported.
Conclusion Mild to moderate hepatic impairment had no 
clinically relevant effect on the pharmacokinetics of a sin-
gle 50 mg dose of afatinib, implying that adjustments to the 
starting dose of afatinib are not considered necessary in this 
patient population.
Keywords afatinib · Hepatic impairment · 
Pharmacokinetics · Human · epidermal growth factor 
receptor (egFr) · tyrosine kinase inhibitor
Introduction
afatinib is an oral irreversible erbB family blocker being 
investigated as a potential treatment for a variety of solid 
tumours [1], including epidermal growth factor recep-
tor (egFr)-mutation-positive non-small cell lung cancer 
(nSClC), and metastatic head and neck cancer [2–6]. It 
was recently approved in various countries for the treat-
ment of locally advanced or metastatic nSClC with acti-
vating egFr mutation(s). afatinib selectively and potently 
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Purpose afatinib, an oral irreversible erbB family 
blocker, undergoes minimal metabolism by non-enzyme-
catalysed adduct formation with proteins or nucleophilic 
small molecules and is predominantly non-renally excreted 
via the entero-hepatic system. this trial assessed whether 
mild or moderate hepatic impairment influences the phar-
macokinetics of afatinib.
Methods this was an open-label single-dose study. Phar-
macokinetic parameters after afatinib 50 mg were inves-
tigated in subjects with mild (n = 8) or moderate (n = 8) 
hepatic impairment (Child-Pugh a and B) and healthy 
controls (n = 16) matched for age, weight and gender. 
Plasma and urine samples for pharmacokinetic assess-
ment were collected before and up to 10 days after dos-
ing. additional blood samples were drawn to determine ex 
vivo plasma protein binding of afatinib. Primary endpoints 
were comparisons of afatinib Cmax and aUC0–∞ between 
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blocks signalling from all relevant erbB family dimers: 
egFr (erbB1), human egFr-2 (Her2; erbB2) and 
erbB4 [1, 7]. afatinib also blocks transphosphorylation of 
erbB3 [7].
In patients with various solid tumours, peak plasma con-
centrations (Cmax) of afatinib are achieved 2–5 h after dosing 
[8]. afatinib exhibits at least bi-exponential disposition with 
steady state reached within 8 days. afatinib displays a high 
apparent volume of distribution during the terminal phase 
(2,000–3,570 l) and a moderate to high apparent total body 
clearance (geometric mean [gMean] 758–1,430 ml/min) 
over the dose range 20–50 mg once daily [8]. the appar-
ent gMean terminal elimination half-life is 37 h making it 
suitable for once-daily dosing [8]. after repeated dosing, 
there is at least twofold accumulation of afatinib based on 
area under the plasma concentration–time curve (aUC) or 
Cmax estimates with no further accumulation in subsequent 
cycles [8]. Intake of high-fat/high-caloric food significantly 
decreased the bioavailability (aUC) of afatinib by ~39 % 
[9]; it is therefore recommended that patients take afatinib 
fasted [10]. Food intake should be avoided 3 h before and 
1 h after afatinib administration. afatinib undergoes mini-
mal metabolism, which is governed by non-enzyme-cata-
lysed adduct formation with proteins or nucleophilic small 
molecules, and is predominantly non-renally excreted via 
the entero-hepatic system [11]. Preclinical studies indicated 
that protein binding was likely to be moderate to high [12]. 
the in vitro metabolic profile and pharmacokinetic data 
suggest no interaction between afatinib and cytochrome 
P-450 substrates [11]. the highest dose intended for clinical 
use is 50 mg once daily.
In view of the biliary excretion and high plasma protein 
binding of afatinib, it is important to characterize the phar-
macokinetics of afatinib in subjects with hepatic impair-
ment. Here, we report data from a Phase I trial in healthy 
volunteers and hepatically impaired patient volunteers that 
was conducted to assess the impact of different degrees of 
hepatic impairment on the pharmacokinetics and safety of 
afatinib.
Methods
this was a single-centre, open-label, single-dose, dose-
escalation study (nCt01298063) using a matched-group 
design. the study protocol was approved by an independ-
ent ethics committee (ethik-Kommission der landesär-
ztekammer Schleswig–Holstein, Bad Segeberg, germany) 
and competent authority (BfarM, Bonn, germany), and 
conducted in accordance with the Declaration of Helsinki. 
Written informed consent was obtained from all subjects 
before study entry.
Subjects
Male or female non-smoker subjects aged 18–75 years 
and with a body mass index between 18.5 and 34.0 kg/m2 
with chronic liver disease stable for at least 3 months were 
enrolled into two pre-specified groups: (a) mild hepatic 
impairment, Child-Pugh a (scores 5 or 6) [13], and (b) 
moderate hepatic impairment, Child-Pugh B (scores 7–9). 
each individual was matched with a healthy control of the 
same gender, age (±10 years), weight (±10 %) and, if pos-
sible, creatinine clearance (±30 ml/min) according to the 
Cockcroft–gault formula (table 1). Healthy subjects were 
eligible based on the lack of clinically relevant history or 
physical examination and electrocardiography (eCg) find-
ings, vital signs and clinical laboratory tests. Overall, cre-
atinine clearance was >70 ml/min for healthy volunteers 
and >40 ml/min for subjects with hepatic impairment.
exclusion criteria in hepatic impaired subjects were 
severe cardiovascular disorders in the preceding 6 months; 
Table 1  Baseline characteristics of the study population included in pharmacokinetic analysis
results presented as mean ± SD unless otherwise stated
a
 Matched to subjects with mild hepatic impairment
b



















afatinib dose (mg) 50 50 50 50 30 30/50
Male [no. (%)] 6 (75.0) 6 (75.0) 5 (62.5) 5 (62.5) 3 (100) 25 (71.4)
age (years) 53.9 ± 9.0 55.9 ± 12.6 54.8 ± 9.0 53.1 ± 7.9 64.3 ± 6.1 55.3 ± 9.5
White race [no. (%)] 8 (100) 8 (100) 8 (100) 8 (100) 3 (100) 35 (100)
Height (cm) 178.8 ± 8.4 175.3 ± 8.4 171.6 ± 9.7 173.0 ± 11.7 180.0 ± 1.7 175.1 ± 9.3
Body mass index (kg/m2) 27.1 ± 4.0 28.4 ± 3.9 26.8 ± 3.8 26.0 ± 2.0 25.1 ± 5.6 26.9 ± 3.6
Creatinine clearance (ml/min) 91.4 ± 20.3 101.0 ± 32.9 87.3 ± 22.6 90.8 ± 14.2 75.5 ± 8.8 91.2 ± 22.5
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significant or recent acute gastrointestinal disorders; 
hepatic encephalopathy >grade 2 by number connection 
test; changes in chronic medication in the 4 weeks prior 
to trial drug administration (other than discontinuation of 
medications known to interact with P-glycoprotein); gas-
trointestinal bleeding in past 3 months; serum albumin 
<20 g/l; or haemoglobin <8 g/dl. For both patients and 
healthy controls, treatment with any medication with a half-
life of >24 h in the month before or during the trial, potent 
P-glycoprotein inhibitors or inducers, or any medication 
known to interact with afatinib was prohibited. Women 
who were pregnant, breastfeeding or those of child-bearing 
potential not using adequate contraception for 3 months 
before and during the study were excluded.
Study design and treatments
after an overnight fast (≥10 h), subjects received a single 
oral dose of afatinib (Boehringer Ingelheim Pharma gmbH 
& Co. Kg, germany) administered as a film-coated tablet 
with 240 ml of water in the sitting or standing position. 
Water was allowed ad libitum except 1 h before and 2 h 
after dosing, and standardized meals were served at least 
2 h after dosing. Subjects were closely observed in the 
clinic for at least 24 h after dosing until discharge 48 h later 
and subsequently returned for follow-up blood sampling. 
Follow-up by telephone was arranged 28 days post-dosing.
Pharmacokinetic evaluation
Blood samples were collected into potassium-eDta-anti-
coagulant tubes before and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 
24, 36, and 48 h after dosing, and then at 24-h intervals 
up to 10 days after dosing. all samples were centrifuged 
within 30 min of collection. a 15-ml sample for deter-
mination of plasma protein binding was also collected in 
3 × 4.9 ml vials (monovettes coated with eDta) on day 
1 before dosing and centrifuged at 4,000 rpm for 10 min 
at 4 °C. all plasma samples were stored at −20 °C until 
analysis. Urine was collected in containers before and 0–4, 
4–8, 8–12, 12–24, 24–48 and 48–72 h after dosing. to pre-
vent adsorption losses of afatinib, a detergent (tween 20) 
was added to the containers before urine collection. For 
each collection, the urine was weighed and homogenized 
and aliquots were stored at −20 °C until analysis.
Plasma and urine concentrations of the free base of 
afatinib (BIBW 2992 BS) were analysed using validated 
liquid chromatography-mass spectrometry (HPlC–MS/
MS) methods (nuvisan gmbH, neu-Ulm, germany) [11, 
14]. Plasma concentrations within the validated concen-
tration range were used to calculate the pharmacokinetic 
parameters. the calibration curves for afatinib covered the 
range 0.100–50.0 ng/ml for plasma and 5.00–1,000 ng/ml 
for urine. the lower limit of quantification of afatinib was 
0.100 ng/ml in plasma and 5.00 ng/ml in urine. assay 
performance was assessed by back calculation of calibra-
tion standards, tabulation of the standard curve fit function 
parameters and measurement of quality control samples. 
For HPlC–MS/MS bioanalysis of afatinib plasma and 
urine concentrations, assay accuracy [deviation from nomi-
nal value (%)] and precision [coefficient of variation (%)] 
of quality control samples spiked at three concentrations 
were between 3.9 and 9.6 % for plasma, and between 4.9 
and 8.0 % for urine, respectively.
In vitro plasma protein binding of afatinib was deter-
mined in pre-dose plasma samples after spiking of 
150 nmol/l (=72.9 ng/ml) [14C]-radiolabeled afatinib 
using equilibrium dialysis (Covance laboratories, Har-
rogate, UK). Previous in-house studies demonstrated the 
suitability of this methodology (unpublished data on file, 
Boehringer Ingelheim, Biberach, germany).
Safety evaluation
the safety of afatinib was assessed by 12-lead eCg, vital 
signs (pulse, blood pressure), routine laboratory assess-
ments, adverse event reporting and assessment of global 
tolerability by the investigator. adverse events were graded 
according to the national Cancer Institute Common termi-
nology Criteria for adverse events (CtCae) version 3.0.
For safety reasons, individuals with hepatic impair-
ment were to be dosed in a 3 + 5 design, with three 
patients being treated at the initial dose (Fig. 1). the deci-
sion to proceed with further afatinib administrations at 
higher doses was based on a combined assessment of 
drug-related adverse events and Cmax (gMean) of afatinib 
by interim pharmacokinetic measurements after dos-
ing of three subjects in each hepatic impairment group 
and their respective controls. Subjects with mild hepatic 
impairment were initially dosed with afatinib 50 mg; if 
no subject had a drug-related adverse event of CtCae 
grade ≥3, or <2 subjects had a drug-related adverse 
event of CtCae grade ≥2 and Cmax was ≤30 ng/ml, 
three patients with moderate hepatic impairment were 
then dosed with 30 mg afatinib. If no drug-related toxic-
ity was observed, the remaining five subjects with mod-
erate hepatic impairment received 50 mg afatinib or an 
interim dose of 40 mg if Cmax was >30 ng/ml and ≤60 ng/
ml. these pharmacokinetic thresholds took into consid-
eration that in a trial of healthy subjects receiving single 
doses of afatinib (20, 30, 40 or 50 mg), individual Cmax 
values exceeding 60 ng/ml were well tolerated [15]. Fur-
ther, in a trial of patients with solid tumours who received 
afatinib 30 and 45 mg once daily for 14 days, no drug-
related adverse events of CtCae grade >2 were reported 
and individual Cmax values after the first dose (day 1) 
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did not exceed 100 ng/ml [14]. to allow for additional 
safety monitoring, staggered dosing was preferred in each 
of the subgroups of five subjects (three subjects on 1 day, 
followed by two subjects on the following day). afatinib 
50 mg was used in this study because it is the maximum 
tolerated dose and is the highest dose for therapeutic use.
Statistical analyses
the study planned to recruit up to 38 subjects (see Fig. 1) 
with the aim of entering eight subjects with mild liver 
impairment (at 50 mg afatinib), eight subjects with moder-
ate liver impairment (at either 30, 40 or 50 mg afatinib) and 
eight healthy matched controls to each of this two groups 
(in total 16 healthy subjects). a total of 32 subjects (eight 
per group) receiving 50 mg afatinib for the primary analy-
sis were judged an adequate sample size, in agreement with 
regulatory guidance of pharmacokinetic studies in patients 
with impaired hepatic function [16].
the primary pharmacokinetic endpoints were aUC 
from time zero extrapolated to infinity (aUC0–∞) and Cmax. 
aUC from 0 to the time of the last quantifiable data point 
(aUC0–tz) was a secondary endpoint. the log-transformed 
aUC and Cmax values for afatinib were compared between 
groups using an analysis of variance (anOVa) model 
with ‘hepatic status’ as fixed effect and ‘matched pair’ as 
random effect. the least square means and 90 % confi-
dence intervals (CI) based on the t-distribution were cal-
culated and then back-transformed to the original scale to 
provide gMean and interval estimates for the ratio between 
response under test (liver impaired subjects) and response 
under reference (healthy subjects). For all other parameters, 
descriptive statistics were presented. non-compartmental 
analysis of plasma concentration–time data was performed 
using Winnonlin® Professional network version 5.2 soft-
ware (Pharsight Corporation, Cary, nC, USa). Statistical 
analyses were performed using SaS®, version 9.2 (SaS 
Institute Inc., Cary, nC, USa).
Results
thirty-five subjects were enrolled and completed the study 
(16 healthy subjects, 8 subjects with mild hepatic impair-
ment and 11 with moderate hepatic impairment). thirty-
two subjects received a single dose of 50 mg afatinib, 
and three received a single 30 mg dose. Primary analysis 
was based on 32 subjects who received the 50 mg dose 
(table 1). all 35 patients were included in the assessment 
of safety.
Pharmacokinetics of afatinib
there were no notable differences in the plasma concen-
tration–time profiles between subjects with mild or moder-
ate hepatic impairment and their matched healthy controls 
(Fig. 2). afatinib showed a biphasic disposition profile, 
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Fig. 1  Planned inclusion and dosing progression for hepatic 
impaired subjects according to assessment of adverse events (aes) 
and exposure (Cmax) for afatinib measured by interim pharmacoki-
netics. ae adverse event. the bold lines indicate the trial pathway 
if there was no drug-related toxicity and plasma exposure (Cmax) did 
not exceed defined thresholds. Dotted lines indicate stopping points if 
drug-related toxicity was observed. Thin lines indicate alternative trial 
pathways. the flow chart does not display the inclusion of matched 
healthy subjects
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the last sampling point of 240 h. the extent of exposure as 
indicated by aUC0–∞ and Cmax was generally comparable 
between the matched treatment groups (table 2). For sub-
jects with mild hepatic impairment, the adjusted gMean 
ratio for aUC0‑∞ was 92.6 % (90 % CI 68.0–126.3 %) and 
for Cmax was 109.5 % (90 % CI 82.7–144.9 %), compared 
with healthy control subjects. For subjects with moderate 
hepatic impairment, the corresponding adjusted gMean 
ratios were 94.9 % (90 % CI 72.3–124.5 %) and 126.9 % 
(90 % CI 86.0–187.2 %), respectively (table 3).
For subjects with mild hepatic impairment, median 
time to peak plasma concentration (tmax) was the same as 
matched healthy controls (5 h). For subjects with moderate 
hepatic impairment, tmax occurred earlier than for matched 
healthy controls (4.0 h for moderate impairment vs. 7.5 h 
for healthy controls). the range of tmax values was also 
larger in subjects with hepatic impairment compared with 
matched healthy controls; for mild impairment, values were 
between 0.5 to 8 h versus 3 to 7 h for matched controls, and 
for moderate impairment, values were between 0.5 to 5 h, 
versus 5 to 9 h for matched controls. the gMean terminal 
half-life ranged from 60 to 75 h and was comparable for 
subjects with hepatic impairment and normal hepatic func-
tion (table 2).
there were quantifiable urinary concentrations of 
afatinib over the entire sampling interval (up to 72 h 
post-dose) in all subjects. the total cumulative fraction 
of afatinib excreted in the urine (fe0–72) in subjects with 
hepatic impairment was generally low and comparable with 
matched controls (gMean values between 2.0 and 2.58 %; 
table 2). the gMean excretion profiles showed no notewor-
thy differences between the treatment groups (Fig. 3).
the arithmetic mean ± SD fraction of [14C] afatinib (tar-
get concentration 72.9 ng/ml) bound to plasma proteins in 
pre-dose plasma samples was 94.6 ± 0.7 % in healthy con-
trols (n = 16), 94.1 ± 1.1 % in subjects with mild hepatic 
Fig. 2  geometric mean plasma 
concentration–time profiles 
of single-dose afatinib 50 mg 
in subjects with a mild and b 
moderate hepatic impairment 
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impairment (n = 8) and 93.7 ± 0.7 % in subjects with 
moderate hepatic impairment (n = 11, three subjects that 
received afatinib 30 mg and eight subjects that received 
afatinib 50 mg). the overall mean percentage protein bind-
ing was 94.2 ± 0.9 %.
Safety and tolerability
Single-dose afatinib 50 mg was well tolerated with few 
adverse events. none of the subjects experienced serious 
adverse events or discontinued the study due to an adverse 
event. adverse events were reported in five (26 %) subjects 
with hepatic impairment (three mild, two moderate) and 
one (6 %) healthy control subject. three patients with mild 
hepatic impairment (50 mg afatinib) had adverse events 
that were considered treatment-related. One of these sub-
jects had a grade 3 lipase elevation; however, cholecysto-
lithiasis with sludge phenomenon was observed on abdomi-
nal ultrasound of this subject, suggesting that this was the 
most likely cause of the increase. this subject had a similar 
episode of asymptomatic lipase increase prior to enrolment 
in the clinical trial. the other two treatment-related events 
were grade 2 headache and nausea in one subject and grade 
1 diarrhoea in one subject. all adverse events had resolved 
Table 2  geometric mean pharmacokinetic parameters after a single dose of 50 mg afatinib for subjects with mild or moderate hepatic impair-
ment and matched healthy controls
Ae0–72 amount of unchanged drug excreted into the urine over 72 h, AUC0–tz area under the drug plasma concentration–time curve from time 0 to 
the time of the last quantifiable data point, AUC0–∞ area under the drug plasma concentration–time curve from time 0 to infinity, Cmax maximum 
drug concentration in plasma, CLR,0–72 renal clearance over 72 h, CV % coefficient of variation (%), fe0–72 fraction of oral dose observed in urine 
over 72 h, t1/2 terminal elimination half-life, tmax time to reach Cmax
results are presented as geometric mean (geometric CV %) unless stated otherwise
a
 Median and range
Parameter and unit Mild hepatic  
impairment  
(n = 8)
Matched controls  
to mild hepatic  
impairment (n = 8)




to moderate hepatic 
impairment (n = 8)
Primary endpoints
 aUC0–∞ (ng h/ml) 886 (53.7) 956 (22.7) 934 (31.0) 985 (32.3)
 Cmax (ng/ml) 33.7 (51.7) 30.7 (33.7) 39.5 (40.1) 31.1 (46.0)
Secondary endpoint
 aUC0–tz (ng h/ml) 842 (50.8) 930 (22.5) 904 (31.4) 956 (33.3)
Other endpoints
 tamax (h) 5.0 (0.5–8.0) 5.0 (3.0–7.0) 4.0 (0.5–5.0) 7.5 (5.0–9.0)
 t1/2 (h) 74.9 (47.6) 60.3 (14.9) 64.3 (13.1) 59.9 (28.5)
 ae0–72 (mg) 1.29 (40.5) 1.21 (14.3) 1.04 (47.7) 0.998 (26.6)
 fe0–72 (%) 2.58 (40.5) 2.43 (14.3) 2.07 (47.7) 2.00 (26.6)
 Clr,0–72 (ml/min) 32.7 (37.6) 27.2 (26.4) 24.1 (71.0) 21.5 (32. 8)
Table 3  adjusted gMean ratios for aUC and Cmax of afatinib 50 mg (subjects with hepatic impairment versus controls), % with 90 % CI
AUC0–tz area under the drug plasma concentration–time curve from time 0 to the time of the last quantifiable data point, AUC0–∞ area under the 
drug plasma concentration–time curve from time 0 to infinity, Cmax maximum drug concentration in plasma, gCV geometric coefficient of varia-
tion (%), gMean geometric mean
a
 ratio of gMeans (hepatic impairment subjects to healthy subjects). Statistical assessment of differences in pharmacokinetic parameters 
between patients with mild and moderate hepatic impairment and healthy subjects was performed using separate anOVa models
b
 See table 2 for the individual group means for each treatment group
Parameter and unit Hepatic impairment group gMean ratio (%) (90 % CI)a Intraindividual gCV (%)b
aUC0–∞ (ng h/ml) Mild 92.6 (68.0–126.3) 33.6
Moderate 94.9 (72.3–124.5) 31.6
Cmax (ng/ml) Mild 109.5 (82.7–144.9) 30.3
Moderate 126.9 (86.0–187.2) 42.8
aUC0–tz (ng h/ml) Mild 90.6 (66.9–122.7) 32.8
Moderate 94.5 (71.6–124.8) 32.4
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by the end of the trial. there were no other clinically rel-
evant changes in laboratory parameters, vital signs or eCg.
Discussion
Following administration of a single dose of 50 mg afatinib, 
exposure levels were comparable for subjects with mild or 
moderate hepatic impairment and healthy controls with 
normal liver function. the pharmacokinetic characteris-
tics of afatinib either in healthy subjects or in subjects with 
mild/moderate hepatic impairment within this trial were 
found to be consistent with the pharmacokinetic character-
istics of afatinib in previous trials of cancer patients with 
various advanced solid tumours [8]. thus, mild or mod-
erate hepatic impairment has no relevant influence on the 
pharmacokinetics of afatinib. this result is important since 
afatinib is preferentially eliminated by the entero-hepatic 
system.
the most likely reason why afatinib exposure is not 
increased in subjects with hepatic impairment may relate 
to the pharmacokinetic properties of the drug. afatinib 
exhibits moderate to high plasma protein binding (mean 
fraction bound 94.6 ± 0.7 % at a concentration of 72.9 ng/
ml in healthy volunteers). thus, only a small fraction 
of the total plasma concentration is directly exposed to 
hepatic metabolism and excretion. Metabolism of afatinib 
is negligible [11], resulting in biliary excretion of predomi-
nantly unchanged afatinib. afatinib is a P-gp substrate, and 
unchanged afatinib may be excreted in the liver via P-gp 
in the bile. However, hepatic impairment is not known to 
influence P-gp expression in the liver meaning that mild to 
moderate hepatic impairment is not likely to substantially 
affect the biliary elimination process of afatinib.
Hepatic impairment had no clinically relevant effect on 
the absorption, distribution or elimination of afatinib. the 
terminal half-life of afatinib in all treatment groups was 
similar although the gMean value was about twice that pre-
viously reported [8] (60–75 h in the current study versus 
~37 h). this was most likely due to the longer sampling 
period (240 h) in this trial compared with that in other trials 
(24 or 72 h) [8]. additionally, the lower limit of quantifica-
tion for afatinib in this study (0.1 ng/ml) was lower than 
that in previous studies (0.5 ng/ml). It is possible that the 
observed prolonged elimination may be attributable to cir-
culating covalent adducts, or non-covalent binding in deep 
compartments, given that afatinib is a basic compound with 
high lipophilicity and a large volume of distribution. How-
ever, it is notable that covalent binding accounted only for 
0.02 % of the dose 48 h after dosing in a metabolism study 
Fig. 3  geometric mean 
cumulative urinary excretion of 
afatinib (%) after single-dose 
afatinib 50 mg in subjects with 
a mild and b moderate hepatic 
impairment compared with 
matched healthy controls
Stop time of collection interval [hours]   
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in healthy volunteers [11]. thus, it is considered unlikely 
that covalent binding may act as a relevant storage com-
partment of afatinib. Furthermore, gMean half-life after 
multiple dosing was around 37 h (plasma concentration 
measured until 72 h) [8], which is consistent with 2.8-fold 
accumulation based on aUC [17]. taken together, these 
observations suggest that the extended terminal elimination 
phase when sampling up to 240 h after dosing was not rel-
evant for the accumulation observed after multiple dosing 
and can therefore be considered negligible.
renal excretion was similar in healthy and hepatic 
impaired subjects and was generally low in all treatment 
groups. although this was a single-dose study, the conclu-
sions based on exposure (Cmax and aUC0–∞) data are likely 
to be valid under steady-state conditions, in that single-
dose data predict multiple-dose exposure [8].
the current analysis showing that mild and moderate 
hepatic impairment had no obvious effect on the pharma-
cokinetics of a single afatinib dose is consistent with data 
from a population pharmacokinetic analysis of patients 
with advanced solid tumours receiving continuous doses 
of afatinib [18]. In this analysis, hepatic impairment, 
either based on individual clinical laboratory tests (ala-
nine transaminase, aspartate transaminase and bilirubin) or 
a composite liver dysfunction measure, had no significant 
influence on afatinib exposure. limited data in the data-
set did not allow robust assessment of moderate hepatic 
impairment, and there were no data for patients with severe 
hepatic impairment.
a single dose of afatinib 50 mg was well tolerated by 
most subjects. all adverse events were of mild to moder-
ate intensity. asymptomatic lipase increases have been 
previously reported following one or two doses of afatinib 
40 mg co-administered with multiple doses of ritonavir 
[19]. the overall frequency of adverse events was higher 
in subjects with hepatic impairment compared with healthy 
subjects, which may be due to the poorer health status of 
these subjects. However, the proportion of subjects report-
ing adverse events was in keeping with previous healthy 
volunteer trials [11, 19].
In conclusion, there were no clinically relevant differ-
ences in exposure (Cmax and aUC0–∞) for subjects with 
mild or moderate hepatic impairment compared with 
matched healthy controls after a single dose of afatinib 
50 mg. Based on these data, adjustments to the starting 
dose of afatinib are not considered necessary for patients 
with mild or moderate hepatic impairment. as systemic 
exposure to afatinib was not assessed in patients with 
severe (Child-Pugh C) hepatic dysfunction, no recommen-
dations can be made for this group of patients.
Acknowledgments the clinical study was conducted at CrS 
Clinical research Services Kiel gmbH, Kiel, germany (principal 
investigator, atef Halabi). Plasma protein binding was conducted by 
Dr Peter Kilford and Joanna noctor from Covance laboratories ltd, 
north Yorkshire, UK. Boehringer Ingelheim was responsible for the 
design and conduct of all of the study, and the collection and manage-
ment of the data. the authors were responsible for the analysis and 
interpretation of the data and the preparation of the manuscript.
Conflict of interest this study was sponsored by Boehringer Ingel-
heim Pharma gmbH & Co Kg, germany. DS, SB, HF, Dg, r-gg, 
MU-F, PS, SW and rK are employees of Boehringer Ingelheim. 
MP-S and aH are employees of Clinical research Services, which 
has been contracted by Boehringer Ingelheim as CrO for the conduc-
tion of this study and has received financial support for its services.
Open Access this article is distributed under the terms of the Crea-
tive Commons attribution license which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Solca F, Dahl g, Zoephel a, Bader g, Sanderson M, Klein C, 
Kraemer O, Himmelsbach F, Haaksma e, adolf gr (2012) tar-
get binding properties and cellular activity of afatinib (BIBW 
2992), an irreversible erbB family blocker. J Pharmacol exp ther 
343(2):342–350
 2. Miller Va, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, 
Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino l, tan eH, 
Chao tY, Shahidi M, Cong XJ, lorence rM, Yang JC (2012) 
afatinib versus placebo for patients with advanced, metastatic 
non-small-cell lung cancer after failure of erlotinib, gefitinib, or 
both, and one or two lines of chemotherapy (lUX-lung 1): a 
phase 2b/3 randomised trial. lancet Oncol 13(5):528–538
 3. Yang JC, Shih JY, Su WC, Hsia tC, tsai CM, Ou SH, Yu CJ, 
Chang gC, Ho Cl, Sequist lV, Dudek aZ, Shahidi M, Cong XJ, 
lorence rM, Yang PC, Miller Va (2012) afatinib for patients with 
lung adenocarcinoma and epidermal growth factor receptor muta-
tions (lUX-lung 2): a phase 2 trial. lancet Oncol 13(5):539–548
 4. Sequist lV, Yang JC, Yamamoto n, O’Byrne K, Hirsh V, Mok 
t, geater Sl, Orlov S, tsai CM, Boyer M, Su WC, Bennouna J, 
Kato t, gorbunova V, lee KH, Shah r, Massey D, Zazulina V, 
Shahidi M, Schuler M (2013) Phase III study of afatinib or cispl-
atin plus pemetrexed in patients with metastatic lung adenocarci-
noma with egFr mutations. J Clin Oncol 31(27):3327–3334
 5. Wu Yl, Zhou C, Hu CP, Feng J, lu S, Huang Y, li W, Hou M, 
Shi JH, lee KY, Xu Cr, Massey D, Kim M, Shi Y, geater Sl 
(2014) afatinib versus cisplatin plus gemcitabine for first-line 
treatment of asian patients with advanced non-small-cell lung 
cancer harbouring egFr mutations (lUX-lung 6): an open-
label, randomised phase 3 trial. lancet Oncol 15(2):213–222
 6. Cohen eeW, Fayette J, Cupissol D, DelCampo JM, Clement 
PM, tourani JM, Degardin M, Zhang W, ehrnrooth e, Seiwert 
tY (2012) a randomized, open-label, phase II study of afatinib 
(BIBW 2992) versus cetuximab in recurrent or metastatic squa-
mous cell carcinoma of the head and neck: final data (abstract 
PP101). eur arch Otorhinolaryngol 269(4):1374
 7. li D, ambrogio l, Shimamura t, Kubo S, takahashi M, Chirieac 
lr, Padera rF, Shapiro gI, Baum a, Himmelsbach F, rettig WJ, 
Meyerson M, Solca F, greulich H, Wong KK (2008) BIBW2992, 
an irreversible egFr/Her2 inhibitor highly effective in preclini-
cal lung cancer models. Oncogene 27(34):4702–4711
 8. Wind S, Schmid M, erhardt J, goeldner rg, Stopfer P (2013) 
Pharmacokinetics of afatinib, a selective irreversible erbB family 
275Cancer Chemother Pharmacol (2014) 74:267–275 
1 3
blocker, in patients with advanced solid tumours. Clin Pharma-
cokinet 52(12):1101–1109
 9. Yap ta, Vidal l, adam J, Stephens P, Spicer J, Shaw H, ang J, 
temple g, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer 
P, Futreal a, Calvert H, de Bono JS, Plummer r (2010) Phase 
I trial of the irreversible egFr and Her2 kinase inhibitor 
BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 
28(25):3965–3972
 10. (2014) gilotrif® (afatinib) tablets [prescribing information]. 
Boehringer Ingelheim Pharmaceuticals, Inc., ridgefield, Ct. 
https://www.gilotrif.com/. accessed 11 Feb 2014
 11. Stopfer P, Marzin K, narjes H, gansser D, Shahidi M, Uttere-
uther-Fischer M, ebner t (2012) afatinib pharmacokinetics and 
metabolism after oral administration to healthy male volunteers. 
Cancer Chemother Pharmacol 69(4):1051–1061
 12. european Medicines agency (2013) Committee for Medicinal 
Products for Human Use (CHMP) assessment report for gio-
trif (afatinib). 16 October 2013. http://www.ema.europa.eu/docs/
en_gB/document_library/ePar_-_Public_assessment_report/
human/002280/WC500152394.pdf. accessed 11 Feb 2014
 13. Pugh rn, Murray-lyon IM, Dawson Jl, Pietroni MC, Williams 
r (1973) transection of the oesophagus for bleeding oesophageal 
varices. Br J Surg 60(8):646–649
 14. eskens Fa, Mom CH, Planting aS, gietema Ja, amelsberg a, 
Huisman H, van Doorn l, Burger H, Stopfer P, Verweij J, de 
Vries eg (2008) a phase I dose escalation study of BIBW 2992, 
an irreversible dual inhibitor of epidermal growth factor receptor 
1 (egFr) and 2 (Her2) tyrosine kinase in a 2-week on, 2-week 
off schedule in patients with advanced solid tumours. Br J Cancer 
98(1):80–85
 15. Food and Drug administration Center for Drug evaluation and 
research (2013) afatinib clinical pharmacology nDa review, 
nov 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2
013/201292Orig1s000ClinPharmr.pdf. accessed 30 april 2014
 16. Food and Drug administration (2003) guidance for industry: 
pharmacokinetics in patients with impaired hepatic function: 
study design, data analysis, and impact on dosing and labeling. 
May 2003. http://www.fda.gov/downloads/Drugs/guidanceC
omplianceregulatoryInformation/guidances/ucm072123.pdf. 
accessed 11 Feb 2014
 17. Heise t, graefe-Mody eU, Huttner S, ring a, trommeshauser 
D, Dugi Ka (2009) Pharmacokinetics, pharmacodynamics and 
tolerability of multiple oral doses of linagliptin, a dipeptidyl 
peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes 
Obes Metab 11(8):786–794
 18. Freiwald M, Schmid U, Fleury a, Wind S, Stopfer P, Staab a 
(2014) Population pharmacokinetics of afatinib, an irreversible 
erbB family blocker, in patients with various solid tumors. Can-
cer Chemother Pharmacol 73(4):759–770
 19. Wind S, giessmann t, Jungnik a, Brand t, Marzin K, Bertulis 
J, Hocke J, gansser D, Stopfer P (2014) Pharmacokinetic drug 
interactions of afatinib with rifampicin and ritonavir. Clin Drug 
Investig 34(3):173–182
